Clinuvel Pharmaceuticals Ltd.
CUVLHealthcare|Medical - Pharmaceuticals|AU
$5.10
+0.08 (+1.59%)
Clinical Trials (23)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06109649 A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo | Vitiligo | P3 | Active | 200 | RCT, Open-label | Afamelanotide and NB-UVB Light |
| NCT04578496 A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) | Erythropoietic Protoporphyria | P3 | Completed | 16 | Open-label | Afamelanotide |
| NCT00979745 Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP) | Erythropoietic Protoporphyria | P3 | Completed | 74 | RCT, Double-blind | Afamelanotide, Placebo |
| NCT04053270 Multicentre Phase III Erythropoietic Protoporphyria Study | Erythropoietic Protoporphyria | P3 | Completed | 100 | RCT, Double-blind | Afamelanotide, Placebo |
| NCT01605136 Phase III Confirmatory Study in Erythropoietic Protoporphyria | Erythropoietic Protoporphyria | P3 | Completed | 93 | RCT, Double-blind | Afamelanotide, Placebo |
| NCT04704713 Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE) | Polymorphic Light Eruption | P3 | Completed | 31 | RCT, Double-blind | Afamelanotide, Placebo |
| NCT01382589 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo | Vitiligo | P2 | Completed | 15 | RCT, Open-label | Afamelanotide |
| NCT04425746 Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium | Patients Undergoing Photodynamic Therapy Using Porfimer Sodium | P2 | Completed | 16 | RCT, Double-blind | Afamelanotide, Placebo |
| NCT00829192 Phase II AK Study in Organ Transplant Patients | Actinic Keratoses, Carcinoma, Squamous Cell | P2 | Unknown | 200 | RCT, Double-blind | Afamelanotide (CUV1647), Placebo |
| NCT05159752 A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP) | Xeroderma Pigmentosum | P2 | Unknown | 6 | Open-label | Afamelanotide |
| NCT05210582 A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face | Vitiligo | P2 | Unknown | 6 | Open-label | Afamelanotide |
| NCT04525157 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV) | Vitiligo | P2 | Completed | 21 | RCT, Double-blind | Afamelanotide, Placebo |
| NCT04962503 A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS) | Arterial Ischemic Stroke | P2 | Completed | 6 | Open-label | Afamelanotide |
| NCT05854784 Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP) | Variegate Porphyria | P2 | Completed | 6 | Open-label | Afamelanotide 16 MG |
| NCT00859534 Phase II Solar Urticaria (SU) Pilot Study | Solar Urticaria | P2 | Completed | 5 | Open-label | afamelanotide |
| NCT04943159 Afamelanotide in Patients Suffering With Acne Vulgaris | Acne Vulgaris | P2 | Completed | 3 | RCT, Open-label | Afamelanotide |
| NCT01097044 Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) | Erythropoietic Protoporphyria | P2 | Completed | 77 | RCT, Double-blind | Afamelanotide, Placebo |
| NCT05370235 A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V | Xeroderma Pigmentosum | P2 | Unknown | 6 | Open-label | Afamelanotide |
| NCT06388642 Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients | Erythropoietic Protoporphyria | P1P2 | Completed | 28 | Open-label | Afamelanotide 16mg implant |
| NCT05368857 DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers | Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers | P1 | Completed | 10 | Open-label | Afamelanotide |
| NCT03634137 Implant Pharmacokinetic and Pharmacodynamic Study | Healthy | P1 | Completed | 24 | RCT, Open-label | Afamelanotide Group 1, Afamelanotide Group 2 |
| NCT01430195 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV) | Vitiligo | P1 | Completed | 56 | RCT, Open-label | Afamelanotide |
| NCT00472901 Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE) | Polymorphic Light Eruption (PLE) | Completed | 18 | — | Afamelanotide (CUV1647) |